Document is current
Any future updates will be listed below
-
Authors
Zhong, Xiaolin
Xiao, Hongyang
Lu, Weihong
Chen, Jiayuan
Chao, Fan
Tu, Ruiqin
-
Funding
Funding for this research was provided by:
Xiamen Municipal Healthcare Directed Project (3502Z20224ZD1074)
Xiamen Municipal Healthcare Directed Project (3502Z20224ZD1074)
Xiamen Municipal Healthcare Directed Project (3502Z20224ZD1074)
National Natural Science Foundation of China (82203743)
National Natural Science Foundation of China (82203743)
Science Fund for Distinguished Young Scholars of Fujian Province (2023J05295)
Science Fund for Distinguished Young Scholars of Fujian Province (2023J05295)
- License Information
-
More Information
Article History
Received: 25 November 2024
Accepted: 17 June 2025
First Online: 1 July 2025
Declarations
:
: Ovarian cancer pathological slides in the in-house dataset were obtained from Shanghai Zhuoli Biotechnology Company (Shanghai, China), with ethical approval from the Ethics Committee of Tongxu County People’s Hospital, Henan, China (approval number: ZL-XP201402). All patients provided written informed consent. External validation data were obtained from the TCGA public database, and all methods were performed in accordance with relevant guidelines and regulations.
: The authors declare no competing interests.
